WallStreetZenWallStreetZen

NASDAQ: PHXM
Phaxiam Therapeutics Sa Earnings & Revenue

OverviewEarnings
DividendOwnership

PHXM past revenue growth

How has PHXM's revenue growth performed historically?
Company
-77.09%
Industry
109.79%
Market
14.13%
PHXM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PHXM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

PHXM earnings and revenue history

Current Revenue
$6.6M
Current Earnings
-$12.5M
Current Profit Margin
-191%

PHXM Return on Equity

Current Company
-38.6%
Current Industry
1.3%
Current Market
-0.3%
PHXM's Return on Equity (-38.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PHXM announces earnings.

PHXM Return on Assets

Current Company
-17.3%
Current Industry
-1.5%
PHXM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PHXM Return on Capital Employed

Current Company
-28.82%
Current Industry
11.8%
PHXM has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PHXM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PHXM$6.35M-$14.18M-$12.13M+2.92%N/A
BCLI$0.00-$15.71M-$16.63MN/AN/A
VINC$0.00-$47.95M-$48.85MN/AN/A
NLSP$0.00-$16.38M-$16.50MN/AN/A
APRE$569.16k-$14.44M-$13.29MN/A-96.59%
View Top Biotech Stocks

Phaxiam Therapeutics Sa Earnings & Revenue FAQ

What were PHXM's earnings last quarter?

On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Phaxiam Therapeutics Sa earnings for the quarter were N/A. In the same quarter last year, Phaxiam Therapeutics Sa's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Phaxiam Therapeutics Sa stock.

What was PHXM's earnings growth in the past year?

As of Q4 2023, Phaxiam Therapeutics Sa's earnings has grown year over year. Phaxiam Therapeutics Sa's earnings in the past year totalled -$12.13 million.

What was PHXM's revenue last quarter?

On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 revenue of N/A up N/A year over year. In the same quarter last year, Phaxiam Therapeutics Sa's revenue was N/A.

What was PHXM's revenue growth in the past year?

As of Q4 2023, Phaxiam Therapeutics Sa's revenue has grown -77.09% year over year. This is 186.88 percentage points lower than the US Biotechnology industry revenue growth rate of 109.79%. Phaxiam Therapeutics Sa's revenue in the past year totalled $6.35 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.